

Reinventing Ultrasound Interpretation

Point-of-care decision assisting tool

Ultrasound is everywhere.



1 BILLION

SCANS / YEAR

Used across **70+ medical specialties** worldwide.



60% → 94%
detection range.

**Diagnosis varies widely
between operators.**


Clinician A
"Inconclusive"



Clinician B
"Suspicious"



Clinician C
"Benign"



The Problem:

Inconsistency drives real consequences.

Two doctors evaluating the same scan agree as little as **41% of the time.**



**\$2B+ Spent on
Unnecessary Biopsies**



Stress



Wasted Time



The problem isn't
ultrasound.


It's subjectivity.

No consistent measurement
standard exists.




The solution:


A new way to see what matters.



Standard Scan



Patented
Process



morphometric


Output



Noticeably different. Simple science:

Disease changes vessel structure.

Healthy



Structured

Cancer



Chaotic

Necrosis
(dead tissue)



Absent



Clearly different. Clearly better.


We solve what others can't:

Quantitative vascular truth.



Beyond Doppler Ultrasound

Flow-independent measurement. No angle sensitivity, no operator variability.




Beyond AI Classifiers

Objective metrics, no black-box classification. Science-based results.



Microvascular Visibility

Reveals capillary-level architecture invisible to both Doppler and AI tools.



Patented Signal Processing


Built on peer-reviewed science. Proprietary algorithms, not assumptions.



Find More



Miss Less




Act Faster



The **morphometrix** advantage.

Rapid, reliable, reproducible results for improved decisions.



One Platform.
Multiple
Use Cases.
Minimal Cost.

Vascular
Diagnostics



Cancer
Screening



Health
Monitoring




Veterinary
Imaging



Starting where impact is the highest:

Cancer. Earlier screening, delivered affordably and accessibly.

“Make quality of care transparent and visible” - WHO World Health Assembly, May 2025



Validation:

Morphometrix is partnering with world-leading institutions.

Clinical Partner:



Ongoing **breast** and **prostate** cancer studies.



Technology Partners:



Supported by:



Market size and opportunity:
Morphometrix is positioned to address two adjacent markets totaling more than \$15.7B.

\$2.1B

Annual Cost of False-Positive Breast Cancer Diagnoses

*False-positive breast biopsies US alone. Source: IBM Watson Health / NCI


\$13.6B

Ultrasound Enhancement Market by 2033

*AI-powered ultrasound segment, growing at 28.55% CAGR. Source: Grand View Research, 2026



Forward only market strategy.



The Ask: \$3M Seed


Capital Story

Pre-Seed Raised USD \$1.1M
Seed Round USD \$3M

What it Delivers

24-month runway to:

- Complete clinical validation
- Achieve regulatory clearance
- Deploy first commercial pilots



■ Personnel ■ Regulatory ■ G&A ■ Clinical ■ Market Entry ■ Infrastructure



The Team




Tal Weissman
Co-Founder, CEO



Joseph Grotzky
Co-Founder, COO



Cory Gelmon
Co-Founder, Managing Director



Barry McLeod
Co-Founder, CSO

Advisory Board

Ali Meghoufel

BEng, MEng, PhD
Senior Technical Advisor

Dr. Gilberto de Lima Lopes

MD, MBA, FASCO
Medical Oncologist

Dr. Imtiaz Ali

MD
Cardiovascular Surgeon

Dr. Judson Brandeis

MD
Urologist, National Director of Clinical
Excellence

Dr. Victor Avramenko

MD
Medical Examiner, Family Physician

Isay Lifshitz

C-level Executive and Investor




Join us to explore more opportunities.

www.morphometrix.com



Tal Weissman - CEO
tal.weissman@morphometrix.com



Joseph Grotzky - COO
joseph.grotzky@morphometrix.com




Regulatory Plan.



Health Canada
Class 2 Medical Device



HSA Singapore
Class B Medical Device



APAC Markets
AU · MY · TH · HK

Requirements

- Full technical documentation (IMDRF / CSDT)
- ISO 13485 QMS certification
- Clinical evidence — UHN study
- Intended use: decision-support tool (Class 2)

Requirements

- Abridged pathway using Health Canada approval as reference
- CSDT submission to HSA Medical Devices Branch
- Local authorized representative required
- Post-market surveillance plan

Market Opportunity

- 140M+ population across initial 4 markets
- \$300M+ false-positive market opportunity
- HSA approval recognized by TGA (Australia) and MDA (Malaysia)
- Private clinic entry — no public tender required



Regulatory Plan - USA



FDA Breakthrough Device Designation

Pre-submission (Q-Sub) meeting to confirm pathway

FDA 510(k) Class II

Primary pathway via substantial equivalence

QDQ

CAD/CADx software for lesions suspicious for cancer

QIH

Automated radiological image processing software

FDA De Novo

If no suitable predicate establishes new device type

When De Novo Applies

- No predicate device substantially equivalent to Morphometrix's microvascular signal processing approach
- De Novo creates a new device classification and itself becomes the predicate for future entrants — a significant competitive moat
- Requires demonstration of reasonable assurance of safety and effectiveness without substantial equivalence claim

